Download Free Sample
Author
Muni Kumar Meravath is a seasoned Healthcare Market Research Analyst with over 6 years of experience in the healthc.....
FLT3 Inhibitors Market: Competitive Landscape, Pipeline, and Market Analysis 2023
FLT3 Inhibitors Market: Competitive Landscape, Pipeline, and Market Analysis 2023
The receptor tyrosine kinase FMs-like tyrosine kinase 3 (FLT3) is involved in regulating the survival, proliferation, and differentiation of hematopoietic stem/progenitor cells and is expressed in cancer cells. FL-T3 mutations cause ligand-independent cell survival, proliferation, and resistance to apoptosis. FLT3 inhibitors interact with the ATP- binding site of the intracellular tyrosine kinase domain and competitively inhibit ATP binding, thereby preventing autophosphorylation and activation of downstream signaling. FLT3 inhibitors are used in the treatment of chronic myeloid leukemia, precursor cell lymphoblastic leukemia-lymphoma, liver cancer, renal cell carcinoma, thyroid cancer, and others. Sanofi, Bayer, Novartis, Bristol-Myers Squibb, Takeda Oncology, and Exelixis are some of the major players in the market for FLT3 inhibitors. Additionally, there are several drug molecules in the clinical trial phases of pharmaceutical companies for other indications.
Key Market Developments:
Approved Drug Molecules and Brand Names for FLT3 Inhibitors:
Drugs under the Pipeline for FLT3 Inhibitors:
Clinical Activity and Developments of FLT3 Inhibitors:
There are more than 60 products, including about 10 approved drug products and other drugs in the clinical trial phases.
|
Molecule Name |
Number of Studies |
|
Dovitinib (TKI258) |
60 |
|
Rydapt (Midostaurin) |
58 |
|
famitinib (SHR 1020) |
52 |
|
Alunbrig (Brigatinib) |
36 |
|
Inrebic (Fedratinib) |
32 |
|
Turalio (Pexidartinib) |
32 |
|
Crenolanib (ARO-002) |
21 |
|
Linifanib (ABT-869) |
20 |
|
Lestaurtinib (CEP-701) |
15 |
|
Mivavotinib (CB-659) |
15 |
|
Gavreto (Pralsetinib) |
12 |
|
Qinlock (Ripretinib) |
12 |
|
Ruserontinib (SKLB-1028) |
9 |
|
ENMD-2076 |
8 |
|
Max-40279 |
8 |
|
Tandutinib (MLN518) |
8 |
|
Zotiraciclib (TG02) |
8 |
|
Ningetinib (CT053PTSA) |
7 |
|
Emavusertib (CA-4948) |
6 |
|
KC1036 |
4 |
|
MRX2843 |
4 |
|
Amuvatinib (MP470) |
4 |
|
Clifutinib (HEC73543) |
4 |
|
Rebastinib (DCC-2036) |
4 |
|
XY0206 |
3 |
|
Flonoltinib |
3 |
Ponatinib is indicated for chronic myeloid leukemia and precursor cell lymphoblastic leukemia-lymphoma and it is in phase-II for acute myeloid leukemia, biliary cancer, gastrointestinal stromal tumors, lung cancer, squamous cell cancer, and thyroid cancer. Cabozantinib and Sorafenib are marketed for liver cancer, renal cell carcinoma, and thyroid cancer. Cabozantinib is also in phase-III for non-small cell lung cancer and prostate cancer. Sunitinib is used in the treatment of gastrointestinal stromal tumors, pancreatic cancer, and renal cell carcinoma and is in phase-II for alveolar soft part carcinoma, bladder cancer, neuroendocrine tumors, oesophageal cancer, phaeochromocytoma, prostate cancer, and uveal melanoma.
Cancer is one of the leading causes of mortality globally. According to the World Health Organization, China had the highest number of new cases of leukemia (85,404), followed by the USA (61,252), and India (48,419) in 2020. In the case of liver cancer, China had 4,10,038 new cases, followed by Japan (45,663) and the USA (42,284) in 2020. For thyroid cancer, China had the highest number of new cases (2,21,093), followed by the USA (52,912). Bayer’s Nexavar (Sorafenib) had a total sale of US$ 292 million in the year 2022, which was a decline from the year 2021 total sales of US$ 476 million. Exelixis’s Cabometyx (Cabozantinib) had a total sale of US$ 1,376 in the USA in 2022, which was an increase from the sales of US$ 1,054 million in 2021 and the company will see all of the patent expiration for Cabometyx by 2033.
Latin America
Europe
Asia Pacific
Middle East
North America
Download Free Sample Report
Sorafenib (Nexavar), Sutent (Sunitinib), Cabometyx (Cabozantinib tablet), Nintedanib, and Iclusig (Ponatinib) are some of the approved FLT3 inhibitors in the market.
Sanofi, Bayer, Novartis, Bristol-Myers Squibb, Takeda Oncology, and Exelixis are some of the major players in the market for FLT3 inhibitors.
Major indications for FLT3 inhibitors are chronic myeloid leukemia, metastatic malignant gastrointestinal stromal tumor, precursor cell lymphoblastic leukemia-lymphoma, liver cancer, renal cell carcinoma, and thyroid cancer.
There are more than 30 drug molecules in clinical development for FLT3 inhibitors.
Key Market Players
Author
Muni Kumar Meravath is a seasoned Healthcare Market Research Analyst with over 6 years of experience in the healthcare domain, encompassing pharmaceuticals, medical devices, and diagnostics. A graduate in Pharmacy, he possesses a strong foundation in the intricacies of the healthcare sector. He further enhanced his expertise by pursuing an MBA in Pharmaceuticals, equipping him with valuable business acumen. His analytical skills and market insights have contributed to strategic decision-making and enhanced market positioning for various healthcare organizations. Committed to driving innovation and excellence, Muni continues to seek opportunities to improve healthcare delivery through data-driven insights.